



**Date : 12<sup>th</sup> December 2024**

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai- 400051.

Scrip Code : KREBSBIO

Dear Sir / Madam,

**Subject: Reply to clarification for Financial Results -Quick Results**

With reference to your e-mail dated 11<sup>th</sup> December 2024, we would like to inform you that the Company is operating in a single segment i.e. Manufacturing of Drugs and Pharmaceuticals, hence no segment results have been disclosed.

This note was part of notes to unaudited financial results of all the past quarters. However, the said notes was missed to be reported in the Q2 FY 25 unaudited financial results in physical format inadvertently due to clerical error. However this note is part of XBRL reporting made by the Company for the said quarter unaudited financial results.

You are requested to take this as clarification and acknowledge the receipt.

Thanking you,

Yours Faithfully,  
For **Krebs Biochemicals & Industries Limited**

**Rakesh R. Kalbate**  
Company Secretary & Compliance Officer